Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors

• Published in: Annals of biomedical engineering Vol. 43; no. 9; pp. 2291 - 2300
• Main Authors: Stylianopoulos, Triantafyllos, Economides, Eva-Athena, Baish, James W., Fukumura, Dai, Jain, Rakesh K.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2015; Springer Nature B.V
• Subjects: Affinity; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Binding; Biochemistry; Biological and Medical Physics; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Biophysics; Classical Mechanics; Drug Carriers - chemistry; Drug Carriers - pharmacology; Drug delivery systems; Drug Design; Drugs; Effectiveness; Humans; Models, Biological; Nanoparticles; Nanoparticles - chemistry; Nanostructure; Neoplasms - drug therapy; Tumors; Drug delivery; Mathematical modeling; Tumor microenvironment; Nano-carriers
• ISSN: 0090-6964; 1573-9686
• DOI: 10.1007/s10439-015-1276-9

Conventional drug delivery systems for solid tumors are composed of a nano-carrier that releases its therapeutic load. These two-stage nanoparticles utilize the enhanced permeability and retention (EPR) effect to enable preferential delivery to tumor tissue. However, the size-dependency of the EPR, the limited penetration of nanoparticles into the tumor as well as the rapid binding of the particles or the released cytotoxic agents to cancer cells and stromal components inhibit the uniform distribution of the drug and the efficacy of the treatment. Here, we employ mathematical modeling to study the effect of particle size, drug release rate and binding affinity on the distribution and efficacy of nanoparticles to derive optimal design rules. Furthermore, we introduce a new multi-stage delivery system. The system consists of a 20-nm primary nanoparticle, which releases 5-nm secondary particles, which in turn release the chemotherapeutic drug. We found that tuning the drug release kinetics and binding affinities leads to improved delivery of the drug. Our results also indicate that multi-stage nanoparticles are superior over two-stage nano-carriers provided they have a faster drug release rate and for high binding affinity drugs. Furthermore, our results suggest that smaller nanoparticles achieve better treatment outcome.